A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, In The Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3
Principal Investigator
,
Status
Terminated
Date of Study Termination
March 02 2017
Disease Site
Gynecologic [GY]
Cervix
Phase
II
Developmental Therapeutics
No
Primary Objective
To determine the efficacy of Celecoxib to induce complete remission (or partial regression to CIN 1) of CIN 2/3 or CIN 3 as evaluated in the post-treatment excisional biopsy.
To determine the toxicity of Celecoxib (400 mg once daily) as assessed by Common Terminology Criteria for Adverse Events in this patient population of women with CIN 2/3 or CIN 3.
Patient Population
Target Accrual
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.